
Non-Hodgkin Lymphoma
Latest News

Advertisement
Latest Videos

CME Content
Advertisement
More News















Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian Cancer
2
LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Sonrotoclax-Based Regimens Elicit Responses in Relapsed/Refractory MCL
4
Dr Borgen on Matching Treatment to HER2 Biology in Early-Stage HER2-Positive Breast Cancer
5
























































